Neurogene ( (NGNE) ) has shared an update.
Neurogene Inc. has announced a $200 million private placement financing, involving top-tier healthcare funds, to support its innovative genetic therapies for rare neurological diseases. The proceeds are expected to fund the company into the second half of 2027, aiding in the development of its NGN-401 gene therapy for Rett syndrome and other projects. Neurogene aims to maximize the therapeutic impact with its EXACT™ platform, ensuring optimized efficacy and safety in its treatments.
Find detailed analytics on NGNE stock on TipRanks’ Stock Analysis page.
